Abstract
To evaluate the hypocalcemic effect of polyethylene gtycol-conjugated salmon calcitonins (PEG-sCT) in rats, mono-PEGylated sCTs (mono-PEG-sCTs) and unmodified sCT were administered via the intranasal route and serum calcium levels were measured by colorimetric assay using o-cresolphthalein. Mono-PEG-sCTs were prepared with different sizes of succinimidyl succinate monomethoxy PEG molecules (PEG2K, PEG5K, PEG12K) and characterized by HPLC and MALDI-TOF mass spectrometry. Nasal instillation of mono-PEG2K-sCT at a dose of 2 IU/kg resulted in sustained reduction in serum calcium levels over 8 hr, with a maximum reduction (% maxd) of 13% after 6 hr of application. Whereas unmodified sCT showed a transient decrease in serum calcium levels with the maximum reduction (5%) observed after 30 min of administration. The overall reductions in serum calcium levels expressed as the net change in AUC relative to control in 8 hr were 11.9 ± 0.2, 4.6 ± 0.7, and 2.6 ± 0.7% for mono-PEG2K-, mono-PEG5K-, and mono-PEG12K-sCT, respectively, compared to 3.2 ± 0.6% for unmodified sCT. The relative bioavailability of nasally administered 2 IU/kg of mono-PEG2K-sCT was approximately 4-fold higher than nasally administrated unmodified sCT, and the absolute bioavailability was approximately 91% of intravenously injected sCT in 8 hr. It can be concluded that the intranasal absorption of mono-PEG-sCTs was inversely related to the molecular weights of the PEG attached. Of the PEGylated sCTs examined, mono-PEG2K-sCT showed the most pronounced hypocalcemic effect. Therefore the intranasal application would probably be an alternative route of administration for mono-PEG-sCTs in achieving sustained calcium-lowering effects.
Similar content being viewed by others
References
YW Chien SF Chang (1987) ArticleTitleIntranasal drug delivery for systemic medications. Crit Rev Ther Drug Carrier Syst 4 67–194 Occurrence Handle1:CAS:528:DyaL1cXhtVWit7s%3D Occurrence Handle3319200
YW Chien KSE Su SF Chang (1989) Intranasal delivery of peptide/protein drugs, intranasal delivery of nonpeptide molecules, intranasal delivery of diagnostic drugs. YW Chien KSE Su SF Chang (Eds) Nasal systemic drug delivery. Marcel Dekker New York 89–298
AE Pontiroli A Calderara G Pozza (1989) ArticleTitleIntranasal drug delivery: potential advantages and limitations from a clinical pharmacokinetics perspective. Clin Pharm 17 299–307 Occurrence Handle1:CAS:528:DyaK3cXisFChtA%3D%3D Occurrence Handle10.2165/00003088-198917050-00001
L Illum (1992) Nasal delivery of peptides, factors affecting nasal absorption. DJA Crommelin KK Midha (Eds) Topics in pharmaceutical sciences Medpharm Scientific Stuttgart 71–82
DA Eppstein JP Longenecker (1988) ArticleTitleAlternative delivery systems for peptides and proteins as drugs. Crit Rev Ther Drug Carrier Syst 5 99–139 Occurrence Handle1:CAS:528:DyaL1MXot1aqsA%3D%3D Occurrence Handle3052876
VHL Lee A Yamamoto (1990) ArticleTitlePenetration and enzymic barriers to peptide and protein absorption. Adv Drug Deliv Rev 4 171–207 Occurrence Handle1:CAS:528:DyaK3cXhtVClsLo%3D Occurrence Handle10.1016/0169-409X(89)90018-5
AK Banga YW Chien (1988) ArticleTitleSystemic delivery of therapeutic peptides and proteins. Int J Pharm 48 15–50 Occurrence Handle1:CAS:528:DyaL1MXot1ejsg%3D%3D Occurrence Handle10.1016/0378-5173(88)90246-3
C McMartin LEF Hutchinson R Hyde DE Peters (1987) ArticleTitleAnalysis of structural requirement for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci 76 535–540 Occurrence Handle1:CAS:528:DyaL2sXlvFShurg%3D Occurrence Handle10.1002/jps.2600760709 Occurrence Handle2889824
JY Reginster A Albert MP Lecart P Lambelin R Deroisy MA Fontaine P Franchimont (1987) ArticleTitle1-Year controlled randomised trial of prevention of early post-menopausal bone loss by intranasal calcitonin. Lancet 2 IssueID8574 1481–1483 Occurrence Handle1:STN:280:DyaL1c%2Fptlehtg%3D%3D Occurrence Handle10.1016/S0140-6736(87)92619-5 Occurrence Handle2892047
JY Reginster A Albert P Franchimont (1985) ArticleTitleSalmon-calcitonin nasal spray in Paget’s disease of bone: preliminary results in five patients. Calcif Tissue Int 37 577–580 Occurrence Handle1:STN:280:DyaL287jt1yrug%3D%3D Occurrence Handle10.1007/BF02554908 Occurrence Handle3937575
WA Lee RD Ennis JP Longenecker P Bengtsson (1994) ArticleTitleThe bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. Pharm Res 11 747–750 Occurrence Handle1:CAS:528:DyaK2cXjtVOgtr4%3D Occurrence Handle10.1023/A:1018992716621 Occurrence Handle8058647
K Overgaard D Agnusdei MA Hansen E Maioli C Christiansen C Gennari (1991) ArticleTitleDose response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 72 344–349 Occurrence Handle1:CAS:528:DyaK3MXlt1Ort70%3D Occurrence Handle10.1210/jcem-72-2-344 Occurrence Handle1846873
KC Lee SC Moon MO Park JT Lee DH Na SD Yoo HS Lee PP DeLuca (1999) ArticleTitleIsolation, characterization and stability of positional isomers of mono-PEGylated salmon calcitonins. Pharm Res 16 818–823 Occurrence Handle1:CAS:528:DC%2BD3cXhtlWksb8%3D
KC Lee KK Tak MO Park JT Lee BH Woo SD Yoo HS Lee PP DeLuca (1999) ArticleTitlePreparation and characterization of polyethylene glycol modified salmon calcitonins. Pharm Devel Technol 4 269–275 Occurrence Handle1:CAS:528:DyaK1MXivFGrtbk%3D Occurrence Handle10.1081/PDT-100101361
KC Lee EE Soltis PW Newman KW Burton RC Mehta PP DeLuca (1991) ArticleTitleIn vivo assessment of salmon calcitonin sustained release from biodegradable microspheres. J Control Rel 17 199–206 Occurrence Handle1:CAS:528:DyaK38XhtFWnsw%3D%3D Occurrence Handle10.1016/0168-3659(91)90059-M
S Hirai T Yasbiki H Mima (1981) ArticleTitleEffect of surfactants to nasal absorption of insulin in rats. Int J Pharm 9 165–172 Occurrence Handle1:CAS:528:DyaL3MXlslGksrc%3D Occurrence Handle10.1016/0378-5173(81)90009-0
NG Schipper SG Romeijn J Verhoef FW Merkus (1994) ArticleTitleHypocalcemic effect of salmon calcitonin following single and repeated nasal and intravenous administration in young rabbits. Calcif Tissue Int 54 50–55 Occurrence Handle1:CAS:528:DyaK2cXjtlWjs70%3D Occurrence Handle10.1007/BF00316290 Occurrence Handle8118754
CR Behl HK Pimplaskar AP Sileno WJ Xia JC deMeireles VD Romeo (1998) ArticleTitleOptimization of systemic nasal drug delivery with pharmaceutical excipients. Adv Drug Del Rev 29 117–133 Occurrence Handle1:CAS:528:DyaK2sXnvFGgsbo%3D Occurrence Handle10.1016/S0169-409X(97)00064-1
LJ Deftos JJ Nolan BL Seely PL Clopton GJ Cote CL Whitham LJ Florek TA Christensen MR Hill (1997) ArticleTitleIntrapulmonary drug delivery of salmon calcitonin. Calcif Tissue Int 61 345–347 Occurrence Handle1:CAS:528:DyaK2sXmsFCltbY%3D Occurrence Handle10.1007/s002239900345 Occurrence Handle9312206
M Azria (1989) The calcitonins: physiology and pharmacology. Karger Basel
K Morimoto M Miyazaki M Kakemi (1995) ArticleTitleEffects of proteolytic enzyme inhibitors on nasal absorption of salmon calcitonin in rats. Int J Pharm 113 1–8 Occurrence Handle1:CAS:528:DyaK2cXms1entLs%3D Occurrence Handle10.1016/0378-5173(94)00158-2
SR Lang W Staudenmann P James H-J Manz R Kessler B Galli H-P Moser A Rummelt HP Merkle (1996) ArticleTitleProteolysis of human calcitonin in excised bovine nasal mucosa: elucidation of the metabolic pathway by liquid secondary ionization mass spectrometry (LSIMS) and matrix-assisted laser desorption ionization mass spectrometry (MALDI). Pharm Res 13 1679–1685 Occurrence Handle1:CAS:528:DyaK28XnsVOiuro%3D Occurrence Handle10.1023/A:1016492723930 Occurrence Handle8956334
MD Donovan GL Flynn GL Amidon (1990) ArticleTitleAbsorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res 7 863–868 Occurrence Handle1:CAS:528:DyaK3cXlsFylsr8%3D Occurrence Handle10.1023/A:1015921101465 Occurrence Handle2235883
Acknowledgements
This work was supported by grant No. 2000-2-21700-001-3 from the Korea Science & Engineering Foundation and partially by the Brain Korea 21 Program of the Ministry of Education.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, K., Park, MO., Na, D. et al. Intranasal Delivery of PEGylated Salmon Calcitonins: Hypocalcemic Effects in Rats . Calcif Tissue Int 73, 545–549 (2003). https://doi.org/10.1007/s00223-002-0034-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-002-0034-9